Cancer

COVID-19 Vaccine Safe With Checkpoint Inhibitors

Study Followed 400+ Cancer Patients

Researchers at Memorial Sloan Kettering ran the study that tracked 408 patients. Each patient received the first dose of a COVID-19 vaccine within 3 months of starting or stopping ICI therapy.

About 7% of study patients had an immune-related adverse event (irAE) — a side effect related to the immune system and inflammation. Patients on ICI therapy commonly experience irAEs, with or without prior COVID vaccination.

In the study, researchers tracked the rates of irAEs in patients with various characteristics. They wanted to understand if prior irAEs might reappear after vaccination. They also wanted to see if vaccination would increase irAEs for patients starting new ICIs.

They found the following rates of irAEs for these patient groups:

  • Patients who had experienced an irAE before vaccination: 6%
  • Patients who started a new ICI after vaccination: 17%

According to researchers, these rates are comparable to those of unvaccinated patients. This means the COVID-19 vaccine did not boost the rates of irAEs from ICI therapy.

Source link
#COVID19 #Vaccine #Safe #Checkpoint #Inhibitors

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *